https://scholars.lib.ntu.edu.tw/handle/123456789/570871
標題: | Hepatitis B virus: New therapeutic perspectives | 作者: | Lin C.-L. HUNG-CHIH YANG JIA-HORNG KAO |
公開日期: | 2016 | 出版社: | Blackwell Publishing Ltd | 卷: | 36 | 起(迄)頁: | 85-92 | 來源出版物: | Liver International | 摘要: | Current antiviral therapies have dramatically improved the long-term outcomes of patients with chronic hepatitis B virus (HBV) infection. Both interferon (IFN) and nucleos(t)ide analogue (NA) treatments have been shown to reduce the progression of liver disease in chronic hepatitis B (CHB) patients. However, persistent covalently closed circular DNA (DNA) can result in a viral relapse after discontinuation of antiviral treatment. On the basis of extensive research on the HBV lifecycle and virus-host interactions, several new agents focusing on viral and host targets are under development to cure HBV. New polymerase inhibitors, tenofovir alafenamide and besifovir provide effective and safer treatment for CHB patients. Agents targeting DNA, such as engineered site-specific nucleases and RNA interference therapeutics could eliminate DNA or silence DNA transcription. Inhibitors of HBV nucleocapsid assembly suppress capsid formation and prevent synthesis of HBV DNA. The HBV entry inhibitor, Myrcludex-B, has been shown to effectively inhibit amplification of DNA as well as the spread of intrahepatic infection. Agents targeting host factors that enhance innate and adaptive immune responses, including the lymphotoxin-β receptor agonist, toll-like receptor agonist, immune checkpoint inhibitors and adenovirus-based therapeutic vaccine, could play a critical role in the elimination of HBV-infected cells. With all of these promising approaches, we hope to reach the ultimate goal of a cure to HBV in the near future. ? 2016 John Wiley & Sons A/S. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84952759635&doi=10.1111%2fliv.13003&partnerID=40&md5=ff9781ec028ee4a69b5e2c6c19a7eb39 https://scholars.lib.ntu.edu.tw/handle/123456789/570871 |
ISSN: | 1478-3223 | DOI: | 10.1111/liv.13003 | SDG/關鍵字: | antivirus agent; besifovir; complementary DNA; hepatitis B(e) antigen; nucleocapsid protein; tenofovir alafenamide; antivirus agent; circular DNA; lipopeptide; myrcludex-B; virus DNA; antiviral therapy; cancer incidence; cancer prevention; clinical trial (topic); controlled clinical trial (topic); disease course; drug targeting; hepatitis B; Hepatitis B virus; host; human; immune response; liver cell carcinoma; meta analysis (topic); multicenter study (topic); nonhuman; phase 1 clinical trial (topic); protein assembly; randomized controlled trial (topic); Review; virus assembly; virus entry; virus inhibition; virus nucleocapsid; blood; drug effects; Hepatitis B virus; Hepatitis B, Chronic; virus replication; Antiviral Agents; Disease Progression; DNA, Circular; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lipopeptides; Randomized Controlled Trials as Topic; Virus Replication |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。